Take home messages Five tyrosine kinase inhibitors are available, the treatment strategy is still challenging. Baseline risk, comorbidities, and patient and physician expectations play a pivotal role. Treatment-free remission is a new opportunity.
Castagnetti F., Gugliotta G., Soverini S., Baccarani M., Rosti G. (2019). Current treatment approaches in CML. HEMASPHERE, 3(Supplemento), 54-56 [10.1097/HS9.0000000000000201].
Current treatment approaches in CML.
Castagnetti F.
;Gugliotta G.;Soverini S.;Baccarani M.;Rosti G.
2019
Abstract
Take home messages Five tyrosine kinase inhibitors are available, the treatment strategy is still challenging. Baseline risk, comorbidities, and patient and physician expectations play a pivotal role. Treatment-free remission is a new opportunity.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
hs9-3-0054.pdf
accesso aperto
Descrizione: Current treatment approaches in CML
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non opere derivate (CCBYND)
Dimensione
261.04 kB
Formato
Adobe PDF
|
261.04 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
